{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:50:33Z","timestamp":1790383833828,"version":"4.1.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002383","name":"King Saud University","doi-asserted-by":"publisher","award":["RSP2024R74"],"award-info":[{"award-number":["RSP2024R74"]}],"id":[{"id":"10.13039\/501100002383","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","jiac-j.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jiac.2024.07.013","type":"journal-article","created":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T21:08:56Z","timestamp":1721250536000},"page":"102473","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Dalbavancin for the treatment of bone and joint infections: A meta-analysis"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1508-8693","authenticated-orcid":false,"given":"Thamer A.","family":"Almangour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8504-3779","authenticated-orcid":false,"given":"Marwan A.","family":"Alrasheed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jiac.2024.07.013_bib1","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1093\/cid\/civ482","article-title":"Infectious diseases society of America (IDSA) clinical practice guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults","volume":"61","author":"Berbari","year":"2015","journal-title":"Clin Infect Dis : an official publication of the Infectious Diseases Society of America"},{"issue":"1","key":"10.1016\/j.jiac.2024.07.013_bib2","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/cis803","article-title":"Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America","volume":"56","author":"Osmon","year":"2013","journal-title":"Clin Infect Dis : an official publication of the Infectious Diseases Society of America"},{"issue":"6","key":"10.1016\/j.jiac.2024.07.013_bib3","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1093\/jac\/dkh191","article-title":"Antibiotic treatment of gram-positive bone and joint infections","volume":"53","author":"Darley","year":"2004","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"10.1016\/j.jiac.2024.07.013_bib4","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJMcp0910753","article-title":"Clinical practice. Vertebral osteomyelitis","volume":"362","author":"Zimmerli","year":"2010","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jiac.2024.07.013_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/599376","article-title":"Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America","volume":"49","author":"Mermel","year":"2009","journal-title":"Clin Infect Dis : an official publication of the Infectious Diseases Society of America"},{"issue":"5","key":"10.1016\/j.jiac.2024.07.013_bib6","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.ijantimicag.2019.08.007","article-title":"Dalbavancin use in an academic medical centre and associated cost savings","volume":"54","author":"Streifel","year":"2019","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"10.1016\/j.jiac.2024.07.013_bib7","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1056\/NEJMoa1710926","article-title":"Oral versus intravenous antibiotics for bone and joint infection","volume":"380","author":"Li","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiac.2024.07.013_bib8","series-title":"Parsippany, NJ: durata therapeutics","year":"2014"},{"issue":"2","key":"10.1016\/j.jiac.2024.07.013_bib9","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s40121-019-0247-0","article-title":"Dalbavancin use in vulnerable patients receiving outpatient parenteral antibiotic therapy for invasive gram-positive infections","volume":"8","author":"Bork","year":"2019","journal-title":"Infectious diseases and therapy"},{"issue":"4","key":"10.1016\/j.jiac.2024.07.013_bib10","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1128\/AAC.04550-14","article-title":"Extended-duration dosing and distribution of dalbavancin into bone and articular tissue","volume":"59","author":"Dunne","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.jiac.2024.07.013_bib11","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1093\/jac\/dkaa188","article-title":"Dalbavancin for the management of osteomyelitis: a major step forward?","volume":"75","author":"Almangour","year":"2020","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"10.1016\/j.jiac.2024.07.013_bib12","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jsps.2020.02.007","article-title":"Dalbavancin versus standard of care for the treatment of osteomyelitis in adults: a retrospective matched cohort study","volume":"28","author":"Almangour","year":"2020","journal-title":"Saudi Pharmaceut J"},{"issue":"2","key":"10.1016\/j.jiac.2024.07.013_bib13","doi-asserted-by":"crossref","first-page":"ofab589","DOI":"10.1093\/ofid\/ofab589","article-title":"Effectiveness of dalbavancin compared with standard of care for the treatment of osteomyelitis: a real-world analysis","volume":"9","author":"Cain","year":"2022","journal-title":"Open Forum Infect Dis"},{"issue":"6","key":"10.1016\/j.jiac.2024.07.013_bib14","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/23744235.2021.1893898","article-title":"Dalbavancin two dose regimen for the treatment of prosthetic joint infections: new possible options for difficult to treat infectious diseases","volume":"53","author":"Fiore","year":"2021","journal-title":"Infectious diseases (London, England)"},{"issue":"1","key":"10.1016\/j.jiac.2024.07.013_bib15","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofy331","article-title":"Dalbavancin for the treatment of osteomyelitis in adult patients: a randomized clinical trial of efficacy and safety","volume":"6","author":"Rappo","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"8","key":"10.1016\/j.jiac.2024.07.013_bib16","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1093\/jac\/dkac178","article-title":"Dalbavancin in Gram-positive periprosthetic joint infections","volume":"77","author":"Simon","year":"2022","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"10.1016\/j.jiac.2024.07.013_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106210","article-title":"Comparison of dalbavancin to standard-of-care for outpatient treatment of invasive Gram-positive infections","volume":"56","author":"Veve","year":"2020","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"10.1016\/j.jiac.2024.07.013_bib18","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.diagmicrobio.2012.11.024","article-title":"Update of dalbavancin spectrum and potency in the USA: report from the SENTRY Antimicrobial Surveillance Program (2011)","volume":"75","author":"Jones","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"9","key":"10.1016\/j.jiac.2024.07.013_bib19","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1128\/AAC.32.9.1320","article-title":"Vancomycin concentrations in infected and noninfected human bone","volume":"32","author":"Graziani","year":"1988","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.jiac.2024.07.013_bib20","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.diagmicrobio.2018.10.007","article-title":"Dalbavancin for the management of gram-positive osteomyelitis: effectiveness and potential utility","volume":"93","author":"Almangour","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"4","key":"10.1016\/j.jiac.2024.07.013_bib21","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ijantimicag.2017.11.008","article-title":"Dalbavancin in the treatment of different gram-positive infections: a real-life experience","volume":"51","author":"Bouza","year":"2018","journal-title":"Int J Antimicrob Agents"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X24001910?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X24001910?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T11:42:46Z","timestamp":1736768566000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X24001910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1341321X24001910"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2024.07.013","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dalbavancin for the treatment of bone and joint infections: A meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2024.07.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102473"}}